| abstract |
The present invention provides methods, compositions, kits, etc. related to the assessment of progressive multifocal leukoencephalopathy (PML) risk, based upon detecting the presence, absence and/or relative levels of serum antibody to BK virus and/or other indication of BK virus infection of a subject, in a subject and/or a sample of a subject. In certain embodiments, such assessment can also include detection of the presence or absence of serum antibody to JC virus in a subject and/or a sample of a subject, optionally to improve the predictive power of such risk assessment. |